Abbott Laboratories

NYSE:ABT Stock Report

Market Cap: US$177.4b

Abbott Laboratories Valuation

Is ABT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ABT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ABT ($102.67) is trading below our estimate of future cash flow value ($136.31)

Significantly Below Future Cash Flow Value: ABT is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABT?

Key metric: As ABT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ABT. This is calculated by dividing ABT's market cap by their current earnings.
What is ABT's PE Ratio?
PE Ratio27.5x
EarningsUS$6.50b
Market CapUS$177.44b

Price to Earnings Ratio vs Peers

How does ABT's PE Ratio compare to its peers?

The above table shows the PE ratio for ABT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.1x
ISRG Intuitive Surgical
57.3x12.79%US$163.8b
MDT Medtronic
24.1x10.97%US$110.1b
SYK Stryker
38.7x17.09%US$124.8b
BSX Boston Scientific
32.2x17.03%US$93.5b
ABT Abbott Laboratories
27.5x12.09%US$177.4b

Price-To-Earnings vs Peers: ABT is good value based on its Price-To-Earnings Ratio (27.5x) compared to the peer average (38.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does ABT's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EMBC Embecta
3.8x5.68%US$524.10m
MHUA.F Meihua International Medical Technologies
0.8xn/aUS$7.15m
ADVB Advanced Biomed
1.5xn/aUS$6.22m
ARTH.Q Arch Therapeutics
n/an/aUS$4.00
No more companies available in this PE range
ABT 27.5xIndustry Avg. 27.5xNo. of Companies8PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ABT is good value based on its Price-To-Earnings Ratio (27.5x) compared to the US Medical Equipment industry average (27.5x).

Price to Earnings Ratio vs Fair Ratio

What is ABT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.5x
Fair PE Ratio39.9x

Price-To-Earnings vs Fair Ratio: ABT is good value based on its Price-To-Earnings Ratio (27.5x) compared to the estimated Fair Price-To-Earnings Ratio (39.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$102.67
US$132.28
+28.84%
8.54%US$158.00US$113.00n/a25
Mar ’27US$116.35
US$133.39
+14.64%
8.37%US$158.00US$113.00n/a25
Feb ’27US$109.30
US$134.24
+22.82%
9.92%US$169.00US$113.00n/a24
Jan ’27US$125.29
US$144.43
+15.28%
6.15%US$162.00US$122.00n/a25
Dec ’26US$128.01
US$144.43
+12.83%
6.15%US$162.00US$122.00n/a25
Nov ’26US$123.62
US$144.47
+16.86%
5.97%US$162.00US$122.00n/a26
Oct ’26US$133.47
US$142.88
+7.05%
5.92%US$159.00US$122.00n/a25
Sep ’26US$132.66
US$142.48
+7.41%
5.59%US$159.00US$122.00n/a25
Aug ’26US$127.29
US$142.48
+11.94%
5.59%US$159.00US$122.00n/a25
Jul ’26US$136.26
US$141.32
+3.71%
6.70%US$159.00US$120.12n/a26
Jun ’26US$133.58
US$140.57
+5.23%
6.62%US$159.00US$120.12n/a25
May ’26US$130.88
US$140.41
+7.28%
7.33%US$159.00US$111.34n/a25
Apr ’26US$131.69
US$136.68
+3.79%
8.12%US$160.00US$111.34US$102.6724
Mar ’26US$138.01
US$133.83
-3.03%
7.73%US$158.00US$109.00US$116.3524
Feb ’26US$127.93
US$133.08
+4.03%
7.46%US$158.00US$109.00US$109.3024
Jan ’26US$113.11
US$130.20
+15.11%
7.46%US$149.00US$104.00US$125.2924
Dec ’25US$118.77
US$129.87
+9.35%
7.41%US$149.00US$104.00US$128.0124
Nov ’25US$118.60
US$129.17
+8.92%
7.56%US$146.00US$104.00US$123.6224
Oct ’25US$113.56
US$124.29
+9.45%
8.36%US$143.00US$104.00US$133.4723
Sep ’25US$113.27
US$123.81
+9.30%
8.53%US$143.00US$104.00US$132.6622
Aug ’25US$110.15
US$124.61
+13.12%
7.98%US$143.00US$104.00US$127.2922
Jul ’25US$103.20
US$125.15
+21.27%
7.60%US$143.00US$104.00US$136.2622
Jun ’25US$102.19
US$125.15
+22.47%
7.60%US$143.00US$104.00US$133.5822
May ’25US$106.29
US$126.33
+18.86%
7.46%US$143.00US$104.00US$130.8822
Apr ’25US$112.09
US$125.47
+11.94%
7.23%US$141.00US$104.00US$131.6922
US$132.28
Fair Value
22.4% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/31 10:10
End of Day Share Price 2026/03/31 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abbott Laboratories is covered by 50 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Adam FeinsteinBarclays
Matthew MiksicBarclays